49. Notkola V, Timaeus IM, Siiskonen H. Impact on mortality of the AIDS epidemics in northern Namibia assessed using parish registers. AIDS. 2004; 18:1061-1065.
50. Obermeyer CM. HIV in the Middle East. British Medical Journal. 2006; 333:851-854.
51. Okie S. Fighting HIV—lessons from Brazil. New England Journal of Medicine. 2006; 354(19):1977-1981.
52. Reid G, Kamarulzaman A, Sran SK. Malaysia and harm reduction: the challenges and responses. International Journal of Drug Policy. 2007; 18(2):136-140.
53. Rhodes T et al. HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. International Journal of Drug Policy. 2004; 15(1):1-16.
54. Buhrich, Copper y Freed. Rev Mex de Salud Mental 1999. Volumen 22 (2): 49-65.
55. Manuel Sanchez Alaves, Luz Anvarro, Oscar Díaz Ruiz, Oscar Gascar, Galicia Castillo, Francisco Sanchez Narvaez, at el. Aspectos moleculares de la demencia asociada al SIDA. Neurology 1991;41:778-785.
56. Levy RM, Berger JR. HIV anf HTLV infections of the nervous system. In: Tyler KL, Martin JB, eds. Infectious diseases of the central nervous system. Philadelphia: F.A. Davis Co., 1993:47-75.
57. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol
58. 1986;19:517-524.
59. Grant I, Martin A. Neurocognitive disorders associated with HIV infection. In: Grant I, Martin A, eds. Neuropsychology of HIV Infection. New York: Oxford University Press, 1994:3-20.
60. James T. Becker, Ph.D. Gray F, Gherardi R, Scaravilli F. The neuropathology of the acquired immune deficiency syndrome (AIDS). Brain 1988;111:245-266.
61. CDC. Revision of the CDC surveillance case definition for Aquired immunodeficiency syndrome. Morbidity & Mortality Weekly 1987;36(suppl 1S):3-15.
62. McArthur J. Neurologic manifestations of AIDS. Medicine 1987;66:407-437.
63. Working Group of AAN AIDS Task Force: Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology 1991; 41:778-785.
64. Report of a working group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology 41:778-785,1991.
65. Francisco Fernández, MD. Manejo psiquiátrico de la infección por HIV y del SIDA.|Revista de Psiquiatría del Uruguay. 2000; 66 (1).
66. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection Semin Neurol. 2007 Feb; 27 (1):86-92.
67. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC,Clearyp: The brain and AIDS: central nervous system HIV-1 infection and AIDS demencia complex. Science. 1988; 239:586-592.
68. Doranz BJ, Rucker J, Yiy Y: A dual-trophic primary HIV-1 isolate that uses fusin and the β -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactor. Cell. 1996; 85:11491158.
69. Epstein LG, Share LR, Goudsmt J: Neurological and neuropathological features of human immunodeficiency virus infection in children. Ann Neurol. 1998 23:519-523.
70. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, MuckelL: Central nervous system damage produces by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994; 367(6459): 188-193.
71. Lipton SA: Calcium channel antagonists and human inununodeficiency virus coat proteinmediated neuronal injury. Ann Neurol. 1991; 30:110-114.
72. Levig G, Patrizio M, Bernardo A, Petrucci TC, Agresti C: Human immunodeficiency virus coat protein gp120 inhibits the β - adrenergic regulation of astroglial and microglial function. Proc Natl Acad Sci USA. 1993 90:1541-1545.
73. Lipton SA, Gendelman HE: Demencia associated with the acquired immunodeficiency syndrome. N Engl J Med. 1995; 332:934-940.
74. Bagettas G., Corasniti MT, Paoletti A.M., Berliocchi L., Nistico R., Giammariolo A.M., Malorni W., Finazzi-Agro A. HIV-1 gp120--induced Apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2). BiochemBiophys Res Commun, 1998; 244:819-824.
75. Balter M: A second correceptor for HIV in early stages of infection. Science, 1996; 272:1740.
76. Baltimore DC, Feinberg MB. HIV revealed: toward a natural history of infection. N Engl J Med. 1989; 132:1673.
77. Cocchif F, Devico AL, Garzino-Demo A, Lusso P, Gallo RC: Role of β -chemokines in suppressing HIV replication. Science, November 1996; 1394-1395.
78. Belman AL, Diamon G., Dick D. Pediatric Acquired Immunodeficiency syndrome. Neurologic syndromes. Am J Dis Child. 1988; 142:29-35.
79. Johnson RT, Mc Arthur JC, Naravano: The neurobiology of human immunodeficiency virus infection. Faseb J. 1988; J, 2:2970-2981.
80. Warnener CG: AIDS and the immune system. Sci Am. 1993; 269(3): 100- 105.
81. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998; 93:648-659.
82. MAINI CL, PIGORINI F, PAU FM: Cortical cerebral blood flow in HIV-1 related demencia complex. Nucl Med Commun. 1990;11:639-648.
83. Bencherif B, Rottenberg DA. Neuroimaging of the AIDS incompleto en el genoma de ratón. 1998; 12:233-244.
84. Benos DJ, Mc Pherson S, Hahh BH, Chaikin MA, Benvenistes EN: Cytokines and HIV envelope glycoprotein gp120 stimulate Na+/K+ exchange in astrocytes. J Biol Chem. 1994; 269(19): 13811- 13816.
85. Darko DF, Mitler MM, Prospero Gatcia O, Henriksen SJ: Sleep and lentivirus infection: Parallel observations obtained from human and animal studies. SRS Bulletin. 1996; 2(3): 43-51.
86. Benveniste ET, Benos JD: TNF and IFN mediated signal transduction pathways: effects on glial cell gene expression and function. FASEB J. 1995; 9:1577-1584.
87. Brenneman, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB: Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal petide. Nature. 1998; 335:639-642.
88. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA: Identification of determinants on a dual-trophic human immunodeficiency virus type-l envelope glycoprotein that confer usage of CXCR4. J Virol, 1998; 72:2509-2515.
89. Pulliam L, Clapke JA, McGrath MS, Moore D, McGuire D: Monokine products as predictor of AIDS dementia. AIDS. 1996 10(13):1495-1500.
90. Clapham PR: HIV and chemokines: ligands sharing cell-surface receptor. Trends Cell Biol. 1997; 7:264-268.
91. Distefano M, Wilt S, Gray F, Dubois Dalcq M, Chiodi F: HIV type I V3 sequences and the development of dementia during AIDS. AIDS Res Hum Retroviruses. 1996; 12(6): 471-476.
92. Everall IP, Luther PJ, Lantos PL: Neuronal loss in the frontal cortex in HIV infection. Lancet. 1991; 337: 1119-1121.
93. Fouchier Ram, Groenink M, Koottstra NA, Termett M, Huisman HG, Miedema F, Schuitemaked H: Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type I gp12O molecule. J Virol, 1992;66:3183-3187.
94. Lipton SA: Neuronal injury associated with HIV-I: Approaches to treatment. Annu Rev Pharmacol Toxicol. 1998; 38:159-177.
95. Mellors JW: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med. 1995;122:573-579.
96. Navia BA, Eun Sook C, Pepito C, Price RW: The AIDS dementia complex. II. Neuropathology Ann Neurol. 1996; 19:525-535.
97. Phillips TR, Prospero Garcia O, Wheeked DW, Wagaman PC, Lerner DL, Fox HS, Whalen LR, Bloom FE, Elder JH, Henriksen SJ: Neurologic dysfunction caused by a molecular clone of feline immunodeficiency virus, FIV-PPR. J. Neurovirol. 1996; 2(6): 338-396.
98. Power R, Johson RT: HIV-1 associated dementia: Clinical features and pathogenesis. Can J Neurol Sci. 1995; 22:92-100.
99. Granti, Atkinson J, Kesselink JR: Evidence of early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency. Ann Intern Med. 1987; 107:828-836.
100. Jassen, Cornblat DR, Epstein LG, Mc Cathur J,Price RW: Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology, AIDS task force. Neurology. 1989; 39: 119-122.
101. Price RW, Perry RW: IHV, AIDS and the Brain. Raven Pres. Nueva York, 1994.
102. Seihean D, Duyckaerts C, Vazeus R, Bolgert F, Brunet P, Katlama C, Gentilini M, Hauw J: HIV-I-Associated cognitive/motor complex: Absence of neuronal loss in the cerebral neocortex. Neurology. 1993; 43:1492-1499.
103. Wesselingh SL, Tyor WR, Griffin DE: Cytokines and HIVAssociated demencia. En: Cytokines and the CNS. Ransohoff RM, Benveniste EN, (eds) CRC Press. 1996;287-306.
104. Mackewicz CE, Barker E, Levy JA: Role of b-chemokines in suppressing HIV rephcadon. Science. 1996; 274(22): 1393-1394.
105. Pedro Casanova Sotolongo, Pedro Casanova Carrillo, Carlos Casanova Carrillo, Gilda Lima Mompó, Laura Aldana Vilas, Miriam Acosta Batista Manifestaciones neuropsiquiatrícas de la infección por el virus de la inmunodeficiencia humana Rev Cubana Med Milit 2002;31(3):194.
106. Chaka W, Gangaidzo I. Diagnosis of neurologic infections in AIDS patients: possibilities for Zimbawe. Cent Afr J Med 2000;46(5):139-40.
107. Straus DJ. HIV-associated lymphomas. Curr Oncol Rep 2001; 3(3):260-5. 3-6.
108. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000;14(3):222-7.
109. Aspectos neuropsiquiátricos de la infección por el VIH. Bol Of Sanit Panam 1988;105(5-6):737-50.
110. Román GC. Infecciones del sistema nervioso por el retrovirus humano. Rev Neurol 1996;24(130):703-7.
111. De Ronchi D, Faranca I, Forti P, Ravaglia G, Borderi M, Manfredi R, et al. Development of acute psychotic disorders and HIV-1 infection. Int J Psychiatry Med 2000;30(2):173-83.
112. Vitiello B, Vitkovic L. The link between infections and psychiatric diseases. Mental Health 1977;2(4):21-32.
113. Francisco Fernandéz MD, Manejo psiquiátrico de la infección por HIV y del SIDA. Revista de psiquiatría del Uruguay. 2002;Vol 66 Nº 1.